Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.

Jan Jansen1, Luke P Akard, Matthew F Wack

  • 1Indiana Blood and Marrow Transplantation, 1500 Albany #911, Beech Grove, IN 46107, USA. jjansen@ibmtindy.com

Mycoses
|August 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Antarctic Seafloor Annotated Imagery Database.

Scientific data·2026
Same author

Representativeness of the Natura 2000 network for preserving plant biodiversity in the European Union.

Conservation biology : the journal of the Society for Conservation Biology·2025
Same author

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

JCO oncology practice·2025
Same author

Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement.

NEJM evidence·2025
Same author

Best Case/Worst Case-ICU: protocol for a multisite, stepped-wedge, randomised clinical trial of scenario planning to improve communication in the ICU in US trauma centres for older adults with serious injury.

BMJ open·2024
Same author

Restrictive Strategy vs Usual Care for Cholecystectomy in Patients With Abdominal Pain and Gallstones: 5-Year Follow-Up of the SECURE Randomized Clinical Trial.

JAMA surgery·2024
Same journal

Insights Into the Susceptibility of Fungal Infection and STAT3 Genetic Mutations.

Mycoses·2026
Same journal

The Underestimated Role of Environmental Factors in the Prevention of Invasive Fungal Disease: Experience From a European Childhood Cancer Centre.

Mycoses·2026
Same journal

Correction to 'Seroprevalence Screening of Chronic Aspergillus Infection in a Post-Tuberculosis Cohort in Senegal: A Cross-Sectional Study Comparing ELISA and Rapid Diagnostic Tests'.

Mycoses·2026
Same journal

Video-Based Training on Physicians' Proficiency in Invasive Fungal Disease: A Multicentre, Cluster Randomised Controlled Trial.

Mycoses·2026
Same journal

Surgical Outcomes and Exploratory Preoperative Risk Stratification for Invasive Pulmonary Fungal Infections in Paediatric Patients: A Single-Center Retrospective Study.

Mycoses·2026
Same journal

Comparison of DermaGenius and In-House qPCR Methods for Detection of Recalcitrant Dermatophyte Infections: A Practical Approach for Dermatologists and Mycologists.

Mycoses·2026
See all related articles

This study on allogeneic stem-cell transplant patients shows risk-based antifungal prophylaxis effectively reduces invasive fungal infections (IFI). Steroid use was a key factor, with Amphotericin B lipid complex proving well-tolerated and beneficial.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Invasive fungal infections (IFI) are a significant cause of mortality post-allogeneic stem-cell transplantation (SCT).
  • Steroid use is a major risk factor for developing IFI in SCT recipients.
  • Current prophylactic strategies require optimization to mitigate IFI risk.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a risk-based chemoprophylaxis strategy for invasive fungal infections (IFI) in allogeneic stem-cell transplantation (SCT) patients.
  • To assess the impact of steroid dosage on IFI incidence and the effectiveness of Amphotericin B lipid complex (ABLC) in preventing IFI.
  • To determine if a risk-based approach can reduce IFI rates and the influence of steroids as a risk factor.

Main Methods:

Related Experiment Videos

  • An open-label pilot study involving 100 allogeneic SCT patients between 1999 and 2002.
  • Initial prophylaxis with oral fluconazole or itraconazole during neutropenia.
  • Patients on prednisone ≥30 mg/day after day +30 were switched to twice-weekly ABLC (4 mg/kg); lower steroid doses continued oral azole prophylaxis.

Main Results:

  • Seven patients required therapeutic ABLC before day +30 due to suspected/documented IFI (4 aspergillosis, 2 candidaemia).
  • Of 63 patients receiving ABLC prophylaxis, 7 developed IFI (3 candidaemia, 3 aspergillosis, 1 Trichosporon beigelii).
  • Thirty patients not needing ABLC prophylaxis had only one case of candidaemia; ABLC was well-tolerated.

Conclusions:

  • Risk-based chemoprophylaxis using ABLC for high-risk (steroid-treated) patients appears effective in preventing IFI post-allogeneic SCT.
  • The strategy may mitigate the impact of steroid use as a risk factor for IFI.
  • A high incidence of early IFI suggests a need for enhanced prophylaxis in poor-risk patients before day +30.